# Dose-confirmatory Bridging Study in Total Hip Replacement

> **NCT01205932** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 402 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (BAY59-7939)
- **DRUG:** Rivaroxaban (BAY59-7939)
- **DRUG:** Rivaroxaban (BAY59-7939)
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT01205932
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-06
- **Final completion:** 2011-08
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2017-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01205932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01205932, "Dose-confirmatory Bridging Study in Total Hip Replacement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01205932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*